Latest adenosine Stories
Stopping to smell the coffee â€“ and enjoy a cup of it â€“ before your morning workout might do more than just get your juices flowing. It might keep you going for reasons you haven't even considered.
LA JOLLA, Calif., March 4 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced today that it has filed a formulation patent covering its lead product, ATPace. ATPace is a stable liquid formulation of adenosine triposphate (ATP) for intravenous administration.
Phase 3 clinical oversight and regulatory services for Cordex's ATPace arrhythmia drug to be provided by Cato Research LA JOLLA, Calif., Feb. 23 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc.
LA JOLLA, Calif., Feb. 18 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced today that it has submitted to the U.S. Food and Drug Administration (FDA) an amended Phase 3 protocol for ATPace to be reviewed as a Special Protocol Assessment (SPA).
Brain cells called astrocytes help to cause the urge to sleep that comes with prolonged wakefulness, according to a study in mice, funded by the National Institutes of Health. The cells release adenosine, a chemical known to have sleep-inducing effects that are inhibited by caffeine.
Scientists have discovered an unexpected brain mechanism that modulates the regulation of sleep and the consequences of sleep deprivation. The research, published by Cell Press in the January 29th issue of the journal Neuron, opens new avenues for development of treatments for disorders and cognitive deficits associated with sleep loss.
HemoBioTech, Inc. (OTCBB: HMB) (www.hemobiotech.com) announced today that Dr. Arthur P. Bollon, its Chairman & CEO, will make a company presentation at the Rodman & Renshaw 10th Annual Healthcare Conference on November 12, at 12 noon.
By Lydia Gehring During a change of routine many people change their intake of caffeinated beverages. They may miss their morning coffee or perhaps increase their intake of caffeinated soda pops.
LA JOLLA, Calif., Aug. 12 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (BULLETIN BOARD: DSKA) ("Duska") announced today that it has received comments from the U.S.
Clinical Data, Inc. (NASDAQ:CLDA) today announced the acquisition of Adenosine Therapeutics, L.L.C., a developer of drug products based on its extensive portfolio of composition of matter and method of use patents relating to selective adenosine receptor modulators.
- Emitting flashes of light; glittering.